ERBB2 and breast carcinoma: Two separate phase III TROPION-breast trials are now ongoing with dato-DXd versus investigator’s choice of chemotherapy in patients with metastatic TNBC who are not a candidate for a PD-L1 inhibitor (TROPION-Breast02; NCT05374512) and patients with metastatic HR+/HER2- breast cancer who have received at least one or two prior lines of systemic chemotherapy (TROPION-Breast01; NCT05104866).